quinazolines has been researched along with Liver Dysfunction in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (15.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 11 (55.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ge, J; Li, X; Liu, R; Sun, R; Zhang, J; Zheng, Q | 1 |
| Erb-Zohar, K; Kobalava, ZD; Kropeit, D; McCormick, D; Moiseev, VS; Rübsamen-Schaeff, H; Stobernack, HP; Zimmermann, H | 1 |
| Benesch, M; Donnerer, J; Kubesch, K; Lackner, H; Schwinger, W; Sperl, D; Strenger, V; Zach, K | 1 |
| Azuma, J; Fujio, Y; Furukawa, M; Imamura, F; Kijima, T; Komuta, K; Kumanogoh, A; Minami, S; Mori, M; Namba, Y; Nonen, S; Otani, Y; Tachibana, I; Takimoto, T; Tsuruta, N; Uchida, J; Yokota, S | 1 |
| Buschke, S; Fuchs, H; Gansser, D; Goeldner, RG; Halabi, A; Koenen, R; Petersen-Sylla, M; Schnell, D; Stopfer, P; Uttenreuther-Fischer, M; Wind, S | 1 |
| Cheng, NS; Li, FY; Ma, WJ; Mao, H; Shrestha, A; Yang, Q; Zhang, W; Zhou, Y | 1 |
| Atobe, O; Fujimori, A; Hachiya, T; Ikuyama, Y; Imai, A; Shiba, H; Sonehara, K | 1 |
| Demetter, P; Geurs, F; Knape, S; Ponette, J; Ponette, S; Vandewaeter, S | 1 |
| Langmuir, P; Martin, P; Molz, KH; Oliver, S; Read, J; Smith, R; Weil, A | 1 |
| Bing, N; Briley, LP; Budde, LR; Cardon, LR; Cox, CJ; King, KS; Mooser, VE; Preston, AJ; Spraggs, CF; Stein, SH; Whittaker, JC | 1 |
| Cantarini, M; Carmichael, J; Harris, AL; Holt, A; Horak, J; Macpherson, M; Swaisland, A; Swaisland, H; Twelves, C; Verrill, M; White, J | 1 |
| Cinca, R; Graefe-Mody, U; Retlich, S; Ring, A; Rose, P; Waldhauser, L; Woerle, HJ | 1 |
| Brown, KH; de Jonge, MJ; Desar, IM; Lassen, U; Marotti, M; van Herpen, CM | 1 |
| GELFAND, M; WESSELS, P | 1 |
| Bardag-Gorce, F; French, BA; French, SW; Li, J; Nan, L; Wilson, LT; Wu, Y | 1 |
| Furubo, S; Harada, K; Isse, K; Kizawa, K; Nakanuma, Y; Ozaki, S; Sanzen, T; Sasaki, M; Sato, Y; Yasoshima, M | 1 |
| Edelman, MJ; Hohl, RJ; Hollis, DR; Kindler, HL; Lewis, LD; Lichtman, SM; Marshall, JL; Miller, AA; Murry, DJ; Owzar, K; Ratain, MJ; Villalona-Calero, MA | 1 |
| Chang, R; Chang, YW; Dong, SH; Kim, BH; Kim, HJ; Kim, SY; Kim, YW | 1 |
| Pozzi, M | 1 |
| Hillenbrand, P; Sherlock, S | 1 |
1 review(s) available for quinazolines and Liver Dysfunction
| Article | Year |
|---|---|
Evodiamine and rutaecarpine from Tetradium ruticarpum in the treatment of liver diseases.
Topics: Animals; Evodia; Humans; Indole Alkaloids; Liver Diseases; Plants, Medicinal; Quinazolines | 2020 |
5 trial(s) available for quinazolines and Liver Dysfunction
| Article | Year |
|---|---|
Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment.
Topics: Acetates; Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Area Under Curve; Cytomegalovirus Infections; Drug Administration Schedule; Female; Half-Life; Humans; Liver; Liver Diseases; Metabolic Clearance Rate; Middle Aged; Quinazolines; Russia; Severity of Illness Index; Treatment Outcome; Young Adult | 2017 |
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
Topics: Adolescent; Adult; Afatinib; Aged; Area Under Curve; Case-Control Studies; Female; Follow-Up Studies; Humans; Liver Diseases; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Quinazolines; Receptor, ErbB-2; Tissue Distribution; Young Adult | 2014 |
Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment.
Topics: Adult; Aged; Area Under Curve; Female; Humans; Liver Diseases; Male; Middle Aged; Neoplasms; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2013 |
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
Topics: Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Kidney Diseases; Kidney Function Tests; Liver Diseases; Liver Function Tests; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Probability; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2007 |
[Clinical trials of an association of a choleretic (1-morpholinoacetyl-3-phenyl-4-oxo-1,2,3,4-tetrahydroquinazoline hydrochloride), (Rec 14-0127) and phenolphthalein and belladonna extract].
Topics: Atropa belladonna; Cholagogues and Choleretics; Clinical Trials as Topic; Gastrointestinal Diseases; Humans; Liver Diseases; Morpholines; Phenolphthaleins; Phytotherapy; Placebos; Plants, Medicinal; Plants, Toxic; Quinazolines; Tuberculosis, Pulmonary | 1969 |
14 other study(ies) available for quinazolines and Liver Dysfunction
| Article | Year |
|---|---|
Letermovir in paediatric HSCT recipients.
Topics: Acetates; Antiviral Agents; Child; Cytomegalovirus Infections; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Liver Diseases; Quinazolines; Transplant Recipients | 2019 |
Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cytochrome P-450 CYP2D6; Female; Follow-Up Studies; Gefitinib; Humans; Liver Diseases; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Genetic; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
Effects of epidermal growth factor receptor inhibitor on proliferative cholangitis in hepatolithiasis.
Topics: Adult; Aged; Bile Ducts; Cholangitis; Collagen Type I; Endoscopy, Digestive System; Epithelium; ErbB Receptors; Female; Gefitinib; Gene Expression; Glucuronidase; Humans; Hyperplasia; Ki-67 Antigen; Lithiasis; Liver Diseases; Male; Middle Aged; Mucin-3; Proliferating Cell Nuclear Antigen; Protein Kinase Inhibitors; Quinazolines | 2015 |
[Successful Treatment of Non-Small Cell Lung Cancer with Afatinib after Gefitinib-Induced Hepatotoxicity].
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Gefitinib; Humans; Liver Diseases; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2016 |
Successful and well-tolerated second line therapy with cetuximab, irinotecan, and raltitrexed in progressive liver disease due to metastatic colon cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Humans; Irinotecan; Liver Diseases; Liver Neoplasms; Male; Quinazolines; Thiophenes | 2008 |
Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Topics: Adult; Aged; Angiogenesis Inhibitors; Area Under Curve; Female; Humans; Kidney Diseases; Liver Diseases; Male; Middle Aged; Piperidines; Quinazolines | 2010 |
HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.
Topics: Aged; Alanine Transaminase; Antineoplastic Agents; Breast Neoplasms; Case-Control Studies; Female; Genetic Predisposition to Disease; Genotype; HLA-DQ alpha-Chains; HLA-DQ Antigens; Humans; Lapatinib; Liver; Liver Diseases; Liver Function Tests; Middle Aged; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors | 2011 |
The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib.
Topics: Adult; Antineoplastic Agents; Area Under Curve; Female; Gefitinib; Humans; Liver Diseases; Male; Middle Aged; Quinazolines | 2011 |
Pharmacokinetics of linagliptin in subjects with hepatic impairment.
Topics: Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Female; Humans; Linagliptin; Liver Diseases; Male; Middle Aged; Purines; Quinazolines; Severity of Illness Index | 2012 |
ACANTHOCHEILONEMA PERSTANS IN A EUROPEAN FEMALE. A DISCUSSION OF ITS POSSIBLE PATHOGENICITY AND A SUGGESTED NEW SYNDROME.
Topics: Acanthocheilonema; Animals; Ascites; Betamethasone; Biopsy; Diethylcarbamazine; Dipetalonema; Drug Therapy; Female; Filariasis; Heart Diseases; Humans; Liver Diseases; Mansonella; Quinazolines; Sulfonamides; Toxicology; Virulence; White People; Zimbabwe | 1964 |
The p105/50 NF-kappaB pathway is essential for Mallory body formation.
Topics: Animals; Antigens, Nuclear; Blotting, Western; Cells, Cultured; Chemical and Drug Induced Liver Injury; Chlormethiazole; Chromosomal Proteins, Non-Histone; Dihydropyridines; Enzyme Inhibitors; Hepatocytes; Inclusion Bodies; JNK Mitogen-Activated Protein Kinases; Liver; Liver Diseases; Male; MAP Kinase Kinase 4; MAP Kinase Kinase Kinase 1; Mice; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase Kinases; Models, Biological; NF-kappa B; NF-kappa B p50 Subunit; Protein Precursors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction | 2005 |
Inhibition of intrahepatic bile duct dilation of the polycystic kidney rat with a novel tyrosine kinase inhibitor gefitinib.
Topics: Animals; Bile Ducts, Intrahepatic; Dilatation, Pathologic; Disease Models, Animal; ErbB Receptors; Gefitinib; Liver; Liver Diseases; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase 7; Polycystic Kidney Diseases; Protein Kinase Inhibitors; Quinazolines; Rats | 2006 |
Alfuzosin-induced acute liver injury.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Chemical and Drug Induced Liver Injury; Dysuria; Humans; Liver Diseases; Liver Function Tests; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines | 2007 |
Use of metolazone in the treatment of ascites due to liver disease.
Topics: Adult; Ascites; Chlorides; Chronic Disease; Diuretics; Female; Hepatic Encephalopathy; Humans; Hypokalemia; Hyponatremia; Ketones; Liver Diseases; Male; Middle Aged; Nitrogen; Pyrazines; Quinazolines; Spironolactone; Sulfonamides; Uremia | 1971 |